Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology Partners with Capital Institute of Pediatrics for Esophageal Atresia Treatment

- Harvard Apparatus Regenerative Technology (HRGN) collaborates with the Capital Institute of Pediatrics in Beijing to advance treatments for Esophageal Atresia (EA). - The partnership will focus on conducting Investigator Initiated Trials (IITs) to assess the safety and efficacy of HRGN's Cellspan Esophageal Implant (CEI). - This collaboration aims to accelerate regulatory approval in China and improve outcomes for children affected by Esophageal Atresia. - The combined expertise seeks to set new standards in pediatric medicine and provide innovative solutions for this challenging condition.